首页|1例美罗培南致中性粒细胞减少症个案报道并文献分析

1例美罗培南致中性粒细胞减少症个案报道并文献分析

Meropenem-Induced Neutropenia:A Case Report and Literature Review

扫码查看
目的 分析美罗培南致中性粒细胞减少症的临床特点,为临床安全用药提供参考.方法 梳理临床药师参与 1 例美罗培南致中性粒细胞减少症的治疗过程,并采用计算机检索中国知网(CNKI)、万方(WanFang)、维普(VIP)、PubMed、MedSci等数据库中美罗培罗致中性粒细胞减少症的相关文献,检索时限为自建库起至 2023 年 2 月 10 日,从患者人口学特征,美罗培南用法用量,中性粒细胞减少症发生时间、严重程度及临床表现,干预及转归等方面分析美罗培南致中性粒细胞减少症的临床特征.结果 共检索到文献5 801 篇,最终纳入 9 篇,涉及 9 例患者.纳入分析的 10 例患者(包含本研究报道案例 1 例和文献检索案例 9 例)中,男 6 例,女 4 例;年龄不超过 3 岁的 5 例;10 例患者均有明确的用法用量;原发疾病主要为颅内感染和血流感染;药品不良反应的潜伏期为 8~20 d(平均 14.5d);8 例患者为重度中性粒细胞减少症,2 例患者合并发热及皮疹;5 例患者停药后中性粒细胞计数自行恢复正常,5 例患者在停药的基础上加用人粒细胞刺激因子注射液升白细胞治疗后中性粒细胞计数亦恢复正常;1 例患者因未定期随访而未知康复时间,其余 9 例患者平均康复时间为 6.9d.结论 美罗培南致中性粒细胞减少症是罕见和可逆的,潜伏期长,多数患者无明显临床表现,但程度较重.临床使用美罗培南时应密切监测患者的中性粒细胞计数,以便及时发现、及时治疗,保证患者用药安全.
Objective To analyze the clinical characteristics of meropenem-induced neutropenia,and to provide a reference for its safe use in the clinic.Methods A clinical pharmacist's participation in the treatment process of one case of meropenem-induced neutropenia was reviewed,and relevant literature on meropenem-induced neutropenia in databases such as CNKI,WanFang,VIP,PubMed,and MedSci were searched from their inception to February 10,2023.The clinical characteristics of meropenem-induced neutropenia were analyzed from the patient's demographic characteristics,usage and dosage of meropenem,occurrence time of neutropenia,severity and clinical manifestations of neutropenia,intervention,and outcome.Results A total of 5 801 studies were retrieved,and nine studies were included,involving nine patients.Among the ten patients included in the review(including one reported case in this study and nine literature search cases),there were six males and four females,five cases with the age less than or equal to three years old;all 10 patients had clear usage and dosage of meropenem;the primary diseases were mainly intracranial infections and bloodstream infections;the incubation period for adverse drug reactions was 8-20 d(with an average of 14.5 d);eight patients had severe neutropenia,and two patients had fever and rash.Neutrophil counts returned to normal in five patients after drug withdrawal,and in five patients after treatment with Human Granulocyte Stimulating Factor Injection to elevated leukocyte on the basis of drug withdrawal.One patient had an unknown specific recovery time due to lack of regular follow-up,while the average recovery time of the other nine patients was 6.9 d.Conclusion Meropenem-induced neutropenia is rare and reversible,with a long incubation period.Most patients have no obvious clinical manifestations,but the degree is serious.When meropenem is used clinically,the patient's neutrophil count should be closely monitored for timely detection and treatment,to ensure the medication safety of patients.

meropenemneutropeniaadverse drug reaction

陶春、李新艺、宋林、王仲书

展开 >

四川省自贡市第四人民医院,四川 自贡 643000

四川卫生康复职业学院,四川 自贡 643000

美罗培南 中性粒细胞减少症 药品不良反应

四川省自贡市卫生健康委员会科研课题

21yb053

2024

中国药业
重庆市食品药品监督管理局

中国药业

CSTPCD
影响因子:1.369
ISSN:1006-4931
年,卷(期):2024.33(3)
  • 8